SEC Filing Summary: ChromaDex Corporation (10-K)
Business Context and Reporting Period
Company: ChromaDex Corporation (formerly Cody Resources, Inc. post-merger).
Reporting Period: Fiscal year ended January 2, 2010.
Business Overview: ChromaDex supplies phytochemical reference standards, reference materials, and contract services for the dietary supplement, nutraceutical, food, beverage, pharmaceutical, and cosmetic markets. The company operates through subsidiaries ChromaDex, Inc. and Chromadex Analytics, Inc., with headquarters in Irvine, California, and a laboratory facility in Boulder, Colorado. The company is classified as a smaller reporting company and its stock trades on the OTC Bulletin Board.
Key Financial Metrics
| Metric | Fiscal Year 2010 (Ended Jan 2) | Fiscal Year 2009 (Ended Jan 3) |
|---|---|---|
| Net Sales | $5,777,865 | $4,506,301 |
| Gross Profit | $2,041,430 | $1,231,501 |
| Gross Margin | 35.3% | 27.3% |
| Operating Loss | $(892,732) | $(2,064,003) |
| Net Loss | $(907,568) | $(2,104,476) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.07) |
| Cash and Equivalents (Ending) | $471,378 | $1,125,504 |
| Net Cash Used in Operating Activities | $(396,172) | $(1,921,371) |
| Total Assets | $3,565,008 | $4,083,110 |
| Total Liabilities | $2,517,555 | $2,333,947 |
| Stockholders' Equity | $1,047,453 | $1,749,163 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 28% to $5.8 million, driven by increased demand for existing products and new service offerings.
- Improved Profitability: Net loss decreased by 57% to $0.9 million. Gross profit increased 66% due to sales growth outpacing fixed labor and overhead costs.
- Expense Reduction: General and administrative expenses decreased 18% to $2.1 million, primarily due to the absence of one-time legal and accounting costs related to the 2008 merger and private placement that occurred in the prior year.
- Cash Flow Improvement: Net cash used in operating activities improved significantly, dropping from $1.9 million to $0.4 million, reflecting a lower net loss and better working capital management (increased customer deposits and accounts payable).
- Inventory Build-up: Inventory increased 30% to $922,760 as the company stocked larger quantities of raw materials to take advantage of volume pricing.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Capital Needs: Management believes current cash resources are sufficient to fund operations through June 2011. The company is actively seeking to raise additional equity capital privately to fund long-term strategic objectives and operations beyond mid-2011. There is no assurance that financing will be available on favorable terms.
Unusual Items:
- Unfunded Subscription Agreement: On November 29, 2009, the company entered into an agreement with Jinke Group (Hong Kong) Ltd to purchase approximately 1.9 million shares for $1 million. As of the filing date, the company had not received payment for either tranche of this transaction, though the investor indicated terms would be honored.
- Deferred Officer Compensation: The company owes $1,178,206 to two officers in deferred salary, payable when cash reserves permit.
Risks and Contingencies:
- Liquidity Risk: The company has a history of operating losses and requires additional financing to continue operations and development. Failure to raise capital could force a curtailment of operations.
- Regulatory Uncertainty: The company's business relies on FDA regulations (Good Manufacturing Practices) for dietary supplements. Changes in enforcement or interpretation could impact demand for their standards.
- Intellectual Property: Success depends on protecting IP through patents and licenses. The company faces risks of infringement claims and the inability to enforce its own rights.
- Market Volatility: The stock is subject to "Penny Stock" rules and has minimal public trading volume, leading to potential price volatility.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to raise capital before June 2011, as current cash ($471k) is insufficient for long-term strategic goals.
- Unfunded Investment: Confirm the status of the $1 million subscription agreement with Jinke Group (Hong Kong) Ltd, which remains unpaid as of the filing date.
- Related Party Debt: Note the $1.18 million in deferred compensation owed to officers, which represents a significant liability contingent on future cash flow.
- Revenue Concentration: Assess the impact of high-volume product sales (dietary supplement ingredients) which have higher raw material costs and may compress future gross margins.
- Stock Liquidity: Acknowledge the "Penny Stock" status and limited trading volume on the OTC Bulletin Board, which may impact the ability to sell shares.